NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球動物激素療法市場:COVID-19 的增長、趨勢、影響、預測(2021-2026)

Animal Hormone Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 1020425
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
全球動物激素療法市場:COVID-19 的增長、趨勢、影響、預測(2021-2026) Animal Hormone Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
出版日期: 2021年07月01日內容資訊: 英文 115 Pages
簡介

在預測期內,動物激素療法的市場規模預計將以 5.52% 的複合年增長率增長。

隨著 COVID-19 的爆發,動物激素治療行業面臨著兩種模式。最初,當疫情爆發,對肉、蛋、奶和其他動物性食品的需求激增時,該行業面臨著對生長促進劑和性能增強劑的需求激增。動物食品加工不是動物和人類避免人類參與和接近的過程。在 COVID-19 流行的威脅下,必須關閉該單元。因此,市場面臨需求下降。然而,用於動物治療目的的動物激素一直需求旺盛,並為該行業提供了支持。因此,預計 COVID-19 將對動物激素治療市場產生顯著的積極影響。

市場增長的主要特徵是動物原發性缺陷負擔增加、肉類需求增加和牲畜增加等因素。通過專注於用於治療激素缺乏症、腫瘤治療或替代療法的激素,不斷增加的動物疾病負擔正在推動市場。根據2019年4月《動物內分泌疾病發病機制》中的一篇文章,甲亢、I型糖尿病、原發性甲狀旁腺功能亢進、原發性甲狀旁腺功能亢進是小動物內分泌功能障礙,是最常見的疾病。動物激素在動物食品工業中用於育肥和促進生產。

此外,2021 年 6 月,美國農業部報告稱牛肉產量連續一年下降,但對肉雞、火雞和豬肉的需求強勁。此外,世界各地的牲畜數量正在增加,這主要與使用動物激素來改善動物健康有關。美國國家農業統計局根據 2021 年 4 月的一份報告,過去 50 年(1970-2020 年)美國的肉雞產量有所增加。因此,相對於上述事實,預計動物激素市場在預測期內將出現顯著增長。

儘管動物激素療法具有廣泛的用途,但與使用動物激素相關的風險以及與其使用相關的嚴格監管標準會阻礙動物激素療法市場的增長。

本報告調查了全球動物激素治療市場,概述了市場,分析了市場增長和障礙、市場機會、COVID-19 的影響,以及按應用、動物和地區劃分的市場規模變化。它提供系統信息,例如預測、競爭條件和主要公司的簡介。

目錄

第 1 章介紹

第 2 章調查方法

第 3 章執行摘要

第 4 章市場動態

  • 市場概覽
  • 市場驅動力
    • 增加動物激素缺乏的負擔
    • 對肉類的需求增加
    • 增加動物飼養
  • 市場限制
    • 與使用動物激素相關的副作用
    • 與動物激素有關的嚴格政府規定
  • 波特五力分析

第 5 章市場細分

  • 按應用程序
    • 生長促進劑
    • 性能增強器
    • 其他
  • 按動物分類
    • 伴侶動物
    • 牲畜
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美洲

第 6 章競爭形勢

  • 公司簡介
    • Merck &Co. Inc
    • Zoetis, Inc
    • Elanco(Bayer Animal Health)
    • Boehringer Ingelheim
    • Bimeda Animal Health
    • Vetoquinol SA
    • Virbac Group
    • CEVA Sante Animale
    • HIPRA Animal Health
    • Syntex SA
    • Huvepharma
    • Jurox Pty Ltd.

第 7 章市場機會和趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 72125

The Animal Hormone Therapy market studied is expected to grow with an estimated CAGR of 5.52%, over the forecast period.

With the outbreak of COVID-19, the animal hormone therapy industry has faced both patterns. Initially when the pandemic strike, with raise in a sudden demand for meat, eggs, milk, and other animal food products, the industry faced a sudden spike in demand for growth promoters and performance enhancers. Since animal food processing is not such a process where human involvement and proximity are avoided with animals and humans. The units have to shut amid the threat of spreading the COVID-19. Thus, the market faced a demand reduction. However, the animal hormone used for therapeutic purposes for animals remains continuously in demand and has supported the industry. Thus, COVID-19 is expected to show a considerable positive impact on the animal hormone therapy market.

The study market growth is predominantly characterized by factors such as the growing burden of hormonal deficiency diseases in animals, rising demand for meat, and increasing animal husbandry. The growing burden of diseases in animals drives the market by focusing on hormones used in the treatment of hormonal deficiency diseases, neoplasia treatment, or replacement therapy. According to the Pathogenesis of Endocrine Disease in Animals Article of April 2019, hyperthyroidism, type I diabetes mellites, primary hyperparathyroidism, and primary hyperadrenocorticism are the most common diseases in small animals that involves endocrine hypofunction. Animal hormones are used for fattening and production boosting purposes in the animal food industry. Further, in June 2021, the United States Department of Agriculture reported a decline in beef production over a year but a strong demand for broilers, turkey, and pork. Further, the number of animal husbandry is increasing all over the globe which largely concerns with animal hormone use for better health of animals. According to the Report of National Agricultural Statistics Services, United States of America, April 2021, Broiler Production in the United States is increasing from the last 5 decades; 1970-2020. Thus, concerning the above facts, the animal hormone market is expected to witness large growth over the Forecast Period.

Although animal hormone therapy has wide applications, the risk associated with the use of animal hormone and the stringent regulatory norms associated with its use may hamper the growth of the animal hormone therapy market.

Key Market Trends

Livestock Animal Segment is Expected to Boosts Market Over the Forecast Period

Hormones can be used as a supplement or to replace any particular deficient hormone in animals. The steroidal hormones such as androgens, estradiol, progesterone, and testosterone are anabolic hormones used for promoting growth, production, and breeding in animals. The steroidal hormones are either implanted in-ear or injected intramuscularly into the animals.

Livestock animals include cattle, swine, poultry, aquaculture species, etc. The response of hormones varies largely among animals. When the same concentration use of estradiol is used in pigs and cattle to increase meat products, the very less increase in lean meat is seen as compared to cattle. Further, in the United States, any feed ingredients and medicines that are administered to animals are regulated by United States Food and Drug Administration (USFDA). Moreover, According to National Agricultural Statistics Service (NASS) report, the total number of cattle heads in the United States is found 94.8 million in Jan 2019 which is reduced to 93.6 million in Jan 2021. However, in order to meet the rising demand for meat consumption among population, the demand for hormonal therapy is expected to grow in the future.

North America Holds Significant Share in Market and Expected to Grow in the Forecast Period

North America, along with Canada, the United States, and Mexico is one of the very well infrastructure animal health facilities. Along with focusing on continuous research on animal and technological advanced processes for animal products processing, North America is expected to dominate the market over the forecast period.

Moreover, According to the Feb 2020 Report of the FCC Economics, Domestic demand for red meat in Canada has remained robust in 2020. There is a significant rise in the price of beef by 3.5%, 0.7% in pork, and 3% in chicken compared to 2019. Implying that a rise in demand for meat in the market accounts for more business. Further, in June 2021, Poultry World Article reported that net egg production in Canada has raised by 2.1% in the year 2020, accounting for a rise in the value of 3.9% compared to the previous year 2019. The increasing demand for nutritious and healthy animal-derived products directly boosts the demand for performance enhancers and health and growth-promoting feeds and supplies. Further, in June 2021, the United States Department of Agriculture (USDA) announced to invest in mid and small-sized poultry processors and producers of about USD 55.2 million to build capacity and increasing economic opportunity for them across the country. Thus, the government authorities are taking steps to encourage the participation of different level players across the globe to make North American Market, a preferable choice by industry players.

Competitive Landscape

The Animal Hormone Therapy market is highly competitive with several players across the globe. In terms of market share, major players currently dominate the market. With the increasing burden of diseases and technological advancement in animal healthcare, many new players are expected to be part of the animal hormone therapy market over the forecast period. Some of the major players of the market are Merck & Co. Inc, Boehringer Ingelheim, Elanco, Inc, Virbac Group, and Vetoquinol SA.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Hormonal Deficiency Diseases inAnimals
    • 4.2.2 Rising Demand of Meat
    • 4.2.3 Increase in Animal Husbandary
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with Use of Animal Hormones
    • 4.3.2 Stringent Government Regulations Associated with Animal Hormones
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Growth Promotors
    • 5.1.2 Performance Enhancers
    • 5.1.3 Others
  • 5.2 By Animals
    • 5.2.1 Companion Animals
    • 5.2.2 Livestock
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co. Inc
    • 6.1.2 Zoetis, Inc
    • 6.1.3 Elanco (Bayer Animal Health)
    • 6.1.4 Boehringer Ingelheim
    • 6.1.5 Bimeda Animal Health
    • 6.1.6 Vetoquinol SA
    • 6.1.7 Virbac Group
    • 6.1.8 CEVA Sante Animale
    • 6.1.9 HIPRA Animal Health
    • 6.1.10 Syntex SA
    • 6.1.11 Huvepharma
    • 6.1.12 Jurox Pty Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS